{"title":"Psychological inflexibility and its impact on mental health and quality of life: Expanding insights and interventions","authors":"Paul Arjanto, Vando Kristi Makaruku","doi":"10.1016/j.genhosppsych.2025.01.015","DOIUrl":"10.1016/j.genhosppsych.2025.01.015","url":null,"abstract":"","PeriodicalId":12517,"journal":{"name":"General hospital psychiatry","volume":"93 ","pages":"Pages 84-85"},"PeriodicalIF":4.1,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143074393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Letter to the editor concerning: Risk of agranulocytosis and neutropenia in patients with Parkinson's disease psychosis receiving clozapine treatment: A systematic review and meta-analysis. Limveeraprajak N, Makkapavee W, Likhitsathian S, Srisurapanont M. Possibly a greater risk?","authors":"Joseph H. Friedman","doi":"10.1016/j.genhosppsych.2025.01.010","DOIUrl":"10.1016/j.genhosppsych.2025.01.010","url":null,"abstract":"","PeriodicalId":12517,"journal":{"name":"General hospital psychiatry","volume":"93 ","pages":"Pages 80-81"},"PeriodicalIF":4.1,"publicationDate":"2025-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143003628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Anna Rihs , Anna Schoeni , Tamara Scharf , Julian Jakob , Kali Tal , Isabelle Jacot-Sadowski , Jean-Paul Humair , Anja Frei , Martin Brutsche , Nicolas Rodondi , Reto Auer , Stéphanie Baggio
{"title":"Effect of e-cigarettes for smoking cessation on depressive and anxiety symptoms: Secondary analysis of a randomized controlled trial","authors":"Anna Rihs , Anna Schoeni , Tamara Scharf , Julian Jakob , Kali Tal , Isabelle Jacot-Sadowski , Jean-Paul Humair , Anja Frei , Martin Brutsche , Nicolas Rodondi , Reto Auer , Stéphanie Baggio","doi":"10.1016/j.genhosppsych.2025.01.011","DOIUrl":"10.1016/j.genhosppsych.2025.01.011","url":null,"abstract":"<div><h3>Objective</h3><div>This study aims to assess differences in depressive and anxiety symptoms at 6-month follow-up in a smoking cessation trial using e-cigarettes as quitting aids.</div></div><div><h3>Methods</h3><div>We conducted a secondary analysis of the Swiss multicentre ESTxENDS smoking cessation randomized controlled trial (RCT) assessing differences in depressive (Patient Health Questionnaire-9, PHQ-9, range: 0–27) and anxiety symptoms (General Anxiety Disorder-7, GAD-7, range: 0–21) at 6-month follow-up comparing participants who received e-cigarettes to those who received smoking cessation counseling alone.</div></div><div><h3>Results</h3><div>Of 1244 participants 913 completed the PHQ-9 and 884 the GAD-7 at 6-month follow-up. Mean PHQ-9 scores (SD) at 6 months for the intervention group were 3.7 (3.9), control group: 4.0 (4.2); mean GAD-7 scores (SD) at 6 months for the intervention group were 4.6 (4.3), control group: 4.6 (4.4). Multivariable analyses showed no evidence of a clinically relevant intervention effect on the PHQ-9 [coefficient − 0.101, 95 % CI -0.182 to −0.019, <em>p</em> = .016, corresponding to a 0.9 decrease of the original PHQ-9 score] and the GAD-7 scores [coefficient − 0.056, 95 % CI -0.135 to 0.022, <em>p</em> = .160] in the main adjusted models.</div></div><div><h3>Conclusions</h3><div>Among smokers who participated in the ESTxENDS smoking cessation trial, we found distribution of e-cigarettes for smoking cessation in addition to standard counseling compared to counseling alone had no clinically relevant effect on depressive or anxiety symptoms at 6-month follow-up.</div><div>Trial Registration: ClinicalTrials <span><span>NCT03603340</span><svg><path></path></svg></span></div></div>","PeriodicalId":12517,"journal":{"name":"General hospital psychiatry","volume":"93 ","pages":"Pages 67-72"},"PeriodicalIF":4.1,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143003617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Gretchen J. Diefenbach , Sarah Collett , Sonata Black , M. David Rudd , Ralitza Gueorguieva , David F. Tolin
{"title":"The effect of inpatient brief cognitive-behavioral therapy for suicide prevention on post-discharge emergency department utilization: Secondary analysis of a randomized clinical trial","authors":"Gretchen J. Diefenbach , Sarah Collett , Sonata Black , M. David Rudd , Ralitza Gueorguieva , David F. Tolin","doi":"10.1016/j.genhosppsych.2025.01.007","DOIUrl":"10.1016/j.genhosppsych.2025.01.007","url":null,"abstract":"<div><h3>Objective</h3><div>Diefenbach and colleagues (2024) found that inpatient Brief Cognitive-Behavioral Therapy for Suicide Prevention (BCBT-I) reduced the rate of six-month post-discharge psychiatric readmissions compared to treatment as usual (TAU). This treatment effect; however, was limited to inpatients, whom were not diagnosed with substance use disorder (SUD). The aim of this secondary analysis was to determine BCBT-I treatment effects and SUD moderation on post-discharge emergency department (ED) utilization.</div></div><div><h3>Methods</h3><div>Inpatients with a history of suicide attempt were assigned to BCBT-I + TAU (<em>n</em> = 94) or TAU alone (<em>n</em> = 106). Presence and number of ED visits were determined via self-report and electronic medical record review for six months after discharge. Generalized linear models for count and binary data were conducted.</div></div><div><h3>Results</h3><div>Adding BCBT-I to TAU reduced the odds and rate of post-discharge ED visits by three quarters [Odds Ratio estimate = 0.25, 95 % CI:(0.12, 0.46); Rate Ratio estimate = 0.24, 95 % CI:(0.11, 0.53)], but only among participants without SUD. Over one-third (36 %) of ED visits were related to suicide. Findings for suicide-related ED visits mirrored those of all-cause ED visits.</div></div><div><h3>Conclusions</h3><div>Adding BCBT-I to TAU reduced post-discharge ED utilization in participants without SUD. Additional research is needed to improve the efficacy of BCBT-I for patients with SUD.</div></div>","PeriodicalId":12517,"journal":{"name":"General hospital psychiatry","volume":"93 ","pages":"Pages 73-79"},"PeriodicalIF":4.1,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143003639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}